Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06822881 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Name: CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc) — clinical trial record (NCT06822881)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorBeijing GoBroad Hospital

Started2025-02-20

View on ClinicalTrials.gov ↗

Amendment history

2026-03-06

2 amendments v1-v2

2 re-verifications since 2025-09-15, no change to tracked fields

2025-02-07

Original filing

Beijing GoBroad Hospital

35 trials monitored

See 2 trials at risk

Lupus (SLE)

648 trials monitored

See 25 trials at risk

Scleroderma

302 trials monitored

See 9 trials at risk

A Clinical Study Exploring CT1190B in the treatment of patients with moderate to severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc)

Trial Details

NCT Number	NCT06822881
Lead Sponsor	Beijing GoBroad Hospital Collaborators: CARsgen Therapeutics Co., Ltd.
Conditions	Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Enrollment	27 participants
Start Date	2025-02-20
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-10